6505--Emergency Breyanzi

The Department of Veterans Affairs, through Network Contracting Office 22, has awarded a sole-source contract for the procurement of Breyanzi, a patient-specific autologous CAR-T cell therapy, under Federal Supply Schedule Contract 36F79724D0101, with a total value of $364,139.25. This acquisition was justified under FAR 8.405-6(a)(1) due to an urgent and compelling clinical need for a single patient with relapsed or refractory B-cell lymphoma, the exclusive proprietary nature of Breyanzi manufactured only by Bristol-Myers Squibb Company, and the absence of any commercially available alternatives. The contract period of performance is strictly limited to July 1–31, 2026, aligning with the product’s narrow manufacturing and infusion window, and delivery is required at the VA Phoenix Healthcare System in Phoenix, Arizona, where the patient will receive treatment. No competitive solicitation occurred, and no standard FAR contract clauses or evaluation factors were applied, as the award was based solely on regulatory justification and a prior determination of fair and reasonable pricing by the VA National Acquisition Center. The product, packaged and shipped under REMS-certified protocols by McKesson Specialty, must be maintained under frozen conditions throughout transport, with final inspection and acceptance performed by the VA upon delivery. The contractor’s unique entity identifier is UFGKB2B71N12, and the acquisition falls under NAICS code 325412 for pharmaceutical preparation manufacturing. Payment will be processed by the Network Contracting Office 22 in Long Beach, California, and no options, extensions, or additional line items are included. The procurement reflects a best value determination driven by medical necessity and regulatory exclusivity rather than competitive price or technical evaluation.